Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan
Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.
How this was made
The 30-second read
Why it matters
The combination of record revenue growth, multiple $100M+ contracts, and the Personalis acquisition positions Tempus for expanded MRD testing and data moat, likely supporting a bullish market reaction.
Market read
Tempus' strong quarter and acquisition could lift health‑tech and AI‑in‑healthcare equities, reinforcing sector momentum.
What to watch
Potential regulatory scrutiny of data privacy and competition from Natera could temper upside.
Background
Tempus AI, a Nasdaq‑listed precision oncology company, disclosed its September 2026 quarter results and strategic moves.
Market effects
Highlights accelerating AI adoption in oncology, may lift other health‑tech stocks.
U.S. biotech and health‑tech sector could see modest gains.
Shows growing importance of data‑driven cancer care worldwide.
Counterpoint
Acquisition integration risk could delay benefits, and high valuation may already price in growth.
Key entities
- companyTempus AI
U.S. listed precision oncology data and testing firm.
- companyPersonalis
MRD detection specialist being acquired by Tempus.


